A randomized double-blind clinical trial investigating the effects of ellagic acid on glycemic status, liver enzymes, and oxidative stress in patients with non-alcoholic fatty liver disease.
- 2025-01-30
- RCT · n = 44
- BMC complementary medicine and therapies 25(1)
- Sara Mighani
- Rasoul Samimi
- Mohamadreza Rashidi Nooshabadi
- Seyed Amir Farzam
- Hossein Khadem Haghighian
- Maryam Javadi
- PubMed: 39885430
- DOI: 10.1186/s12906-025-04759-4
- High evidence
- Clinical
changes in high-density lipoprotein (HDL), total cholesterol (TC), and fasting blood sugar (FBS) were not significant in any of the groups (P > 0.05)
- Effect
- Neutral
- Effect size
- Small
- Significant
- No
- Dose
- 180 mg per day